文献速递胸部肿瘤

德曲妥珠单抗治疗HER2突变转移性非小细胞肺癌:随机II期DESTINY-Lung02试验主要结果

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
PubMed 文献 · J Clin Oncol · 2023-09-11

DESTINY-Lung02是一项盲法、多中心、II期研究,将152例经治HER2突变转移性非小细胞肺癌患者按2:1随机分配至德曲妥珠单抗5.4 mg/kg或6.4 mg/kg每3周一次。5.4 mg/kg组确认客观缓解率为49.0%,6.4 mg/kg组为56.0%;5.4 mg/kg组安全性更优,药物相关间质性肺病发生率12.9% vs 28.0%。

要点

  • 德曲妥珠单抗5.4 mg/kg和6.4 mg/kg每3周一次均显示有临床意义的缓解。
  • 5.4 mg/kg组确认客观缓解率49.0%,6.4 mg/kg组56.0%。
  • 安全性特征倾向于5.4 mg/kg,药物相关间质性肺病发生率12.9% vs 28.0%。

核心结论

  • 德曲妥珠单抗在两个剂量下均显示出有临床意义的缓解,安全性特征可接受且总体可控,倾向于5.4 mg/kg。

研究设计与样本

  • DESTINY-Lung02是一项盲法、多中心、II期研究。
  • 研究纳入既往接受过含铂治疗的HER2突变(定义为单核苷酸变异和20号外显子插入)转移性非小细胞肺癌患者。
  • 152例患者按2:1随机分配至德曲妥珠单抗5.4 mg/kg或6.4 mg/kg每3周一次。
  • 主要终点为盲法独立中心评审按RECIST v1.1确认的客观缓解率。

主要发现

  • 截至2022年12月23日,5.4 mg/kg组中位随访时间11.5个月(范围1.1-20.6),6.4 mg/kg组11.8个月(范围0.6-21.0)。
  • 5.4 mg/kg组确认客观缓解率49.0%(95%CI 39.0-59.1),6.4 mg/kg组56.0%(95%CI 41.3-70.0)。
  • 5.4 mg/kg组中位缓解持续时间16.8个月(95%CI 6.4-不可估计),6.4 mg/kg组不可估计(95%CI 8.3-不可估计)。
  • 5.4 mg/kg组中位治疗持续时间7.7个月(范围0.7-20.8),6.4 mg/kg组8.3个月(范围0.7-20.3)。

关键数值与推荐

  • 5.4 mg/kg组≥3级药物相关治疗中出现的不良事件发生在101例中的39例(38.6%),6.4 mg/kg组发生在50例中的29例(58.0%)。
  • 5.4 mg/kg组经裁决的药物相关间质性肺病发生在101例中的13例(12.9%),6.4 mg/kg组发生在50例中的14例(28.0%)。
  • 两组≥3级间质性肺病发生率均为2.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2-mutant (HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non-small-cell lung cancer (mNSCLC). METHODS: DESTINY-Lung02, a blinded, multicenter, phase II study, investigated T-DXd 5.4 mg/kg once every 3 weeks for the first time in previously treated (platinum-containing therapy) patients with HER2m mNSCLC and further assessed T-DXd 6.4 mg/kg once every 3 weeks in this population. The primary end point was confirmed objective response rate (ORR) per RECIST v1.1 by blinded independent central review. RESULTS: One hundred fifty-two patients were randomly assigned 2:1 to T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. As of December 23, 2022, the median duration of follow-up was 11.5 months (range, 1.1-20.6) with 5.4 mg/kg and 11.8 months (range, 0.6-21.0) with 6.4 mg/kg. Confirmed ORR was 49.0% (95% CI, 39.0 to 59.1) and 56.0% (95% CI, 41.3 to 70.0) and median duration of response was 16.8 months (95% CI, 6.4 to not estimable [NE]) and NE (95% CI, 8.3 to NE) with 5.4 and 6.4 mg/kg, respectively. Median treatment duration was 7.7 months (range, 0.7-20.8) with 5.4 mg/kg and 8.3 months (range, 0.7-20.3) with 6.4 mg/kg. Grade ≥ 3 drug-related treatment-emergent adverse events occurred in 39 of 101 (38.6%) and 29 of 50 (58.0%) patients with 5.4 and 6.4 mg/kg, respectively. 13 of 101 (12.9%) and 14 of 50 (28.0%) patients had adjudicated drug-related interstitial lung disease (2.0% grade ≥ 3 in each arm) with 5.4 and 6.4 mg/kg, respectively. CONCLUSION: T-DXd demonstrated clinically meaningful responses at both doses. Safety profile was acceptable and generally manageable, favoring T-DXd 5.4 mg/kg.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Goto K, Goto Y, Kubo T, et al. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J Clin Oncol. 2023. PMID: 37694347. doi:10.1200/JCO.23.01361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。